This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Jim Cramer's 'Mad Money' Recap: Got Growth?

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK ( TheStreet) -- Where can investors find the best growth stocks? All over place, if you know where to look, Jim Cramer said on "Mad Money" Tuesday.

In the biotech space, Cramer called out Regeneron (REGN) as one such stock -- it has growth today and, thanks to a robust pipeline of new drugs, for many years to come. The oil patch is littered with high-growth stocks, including EOG Resources (EOG), Cramer continued.

Restaurants Red Robin Gourmet Burgers (RRGB) and Starbucks (SBUX) both have growth, as do retailers Michael Kors (KORS), which delivered a 49% increase in profits and a 23% increase in sales this quarter.

Cramer said just about any stock that deals with mobile, social media or the cloud is growing like gangbusters -- which leads right to this week's Twitter IPO. Just a few weeks ago, Cramer noted, he was at the high end of the range, saying Twitter could be worth up to $20 billion. But today, despite nothing factually changing, $20 billion seems at the low end of the range, with some calling for valuations as high as $50 billion for Twitter.

Cramer said that's a recipe for investors to get hurt, a la the Facebook (FB) IPO last year. He cautioned that the big boys are betting big that uninformed investors will be willing to pay anything for shares of Twitter -- which is why he's once again reminding everyone there are prices at which every stock just becomes uninvestable.

Cramer said he's willing to pay up to $28 a share for Twitter and not a penny more.

Executive Decision:

In the "Executive Decision" segment, Cramer sat down with Dr. Ron Cohen, president and CEO of Acorda Therapeutics (ACOR), a stock that's up 31% so far in 2013 and just delivered a 16-cents-a-share earnings beat.

Cohen said sales of Acorda's multiple sclerosis drug, Ampyra, is the engine that's helping to drive the company forward and Acorda is very fortunate to have such a successful product. Acorda is not a one-hit wonder, however, as the company now has six drugs in clinical studies, including new formulations of ingredients of Amypra that may treat strokes and other conditions.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs